Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SSGJ-706
SSGJ-706+XELOX · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Cohort A | EXPERIMENTAL | - |
| Cohort B | EXPERIMENTAL | - |
| Cohort C | EXPERIMENTAL | - |
| Cohort D | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SSGJ-706+XELOX | DRUG | SSGJ-706 (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, D1-D14, Q3W,up to 6 cycles) . Afterward, SSGJ-706 (administered on Day 1 of each cycle, Q3W) and Capecitabine (1000 mg/m2, p.o., Bid, D1-D14, Q3W) will be used for maintenance treatment. |
| SSGJ-706+Bevacizumab+XELOX | DRUG | SSGJ-706 (administered on Day 1 of each cycle, Q3W)+Bevacizumab (7.5 mg/kg intravenous infusion on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 8 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, D1-D14, Q3W,up to 8 cycles) . Afterward, SSGJ-706 (administered on Day 1 of each cycle, Q3W), Bevacizumab (7.5 mg/kg intravenous infusion on Day 1 of each cycle, Q3W) and Capecitabine (1000 mg/m2, p.o., Bid, D1-D14, Q3W) will be used for maintenance treatment. |
| SSGJ-706+AG | DRUG | SSGJ-706 (administered on Day 1 of each cycle, Q2W)+Albumin-bound Paclitaxel (125 mg/m2 intravenous infusion on Days 1, 8, 15 of each 28-day cycle)+ Gemcitabine(1000 mg/m2 intravenous infusion on Days 1, 8, 15 of each 28-day cycle) . |
| SSGJ-706+TP | DRUG | SSGJ-706 (administered on Day 1 of each cycle, Q3W)+Paclitaxel (175 mg/m2 intravenous infusion on Day 1, Q3W)+ Cisplatin(60-80 mg/m2 intravenous infusion on Day 1, Q3W) . |
Inclusion Criteria: 1. Volunteer to participate in this study, willing to follow all trial procedures, and sign the informed consent form (ICF). 2. Age 18-75 years old, male or female. 3. Has a life expectancy of at least 3 months 4. ECOG score of 0-1. 5. Locally advanced or metastatic tumors of th...
SSGJ-706 is an investigational small molecule being studied for first-line advanced non-small cell lung cancer (NSCLC) and for gastric/gastroesophageal junction adenocarcinoma. It is also being evaluated in combination therapy for advanced gastrointestinal cancers, including metastatic colorectal cancer, pancreatic ductal adenocarcinoma, and oesophageal cancer.
SSGJ-706 is being developed by Sunshine Biopharma Inc., a biopharmaceutical company listed on the stock exchange under the ticker SBFM. The company is conducting clinical trials for this investigational drug in China.
SSGJ-706 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 trials are listed, one recruiting and one not yet recruiting, with a combined planned enrollment of 300 patients.
SSGJ-706 is being studied in two Phase 2 trials. NCT07171606 is a recruiting study of SSGJ-706 monotherapy and combination therapy in advanced NSCLC with 240 patients. NCT07233850 is a not-yet-recruiting study of SSGJ-706 in combination therapy for advanced gastrointestinal cancers with 300 patients.
SSGJ-706+XELOX is an alternative name for SSGJ-706, referring to the drug when used in combination with the chemotherapy regimen XELOX. The drug itself is SSGJ-706, and the combination name is used in the context of its clinical development.